Friday 6 November 2026 Export XERS’s income statement to Excel — free account

Xeris Biopharma Holdings, Inc.

XERS Healthcare Drug Manufacturers Specialty & Generic

Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.

Revenue: +44.2%
EPS: +1,479.0%
Free cash flow: +93.2%
Total debt: −13.6%

Quarter to September 2026, against a year earlier

15.16 2.08 +15.90%

Follow XERS

Alert me

Market cap: $2.4B
P/E: 0.0×
Fwd P/E: −143×
Dividend yield: —
F-score: 8/9
Altman Z: 0.98
Beneish M: −2.58
Dividend safety: n/a

Overview

Xeris Biopharma Holdings, Inc. (XERS) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a P/B ratio of 56.2×. Over the past ten years it has ranged from 0.0× (September 2026) to 101× (June 2026); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.7× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/XERS/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Xeris Biopharma Holdings, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/XERS/metrics/pb-ratio">Xeris Biopharma Holdings, Inc. (XERS) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	92.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	3.4×	38.26%
FY2021	2.4×	(60.87%)
FY2020	6.2×	(51.26%)
FY2019	12.8×	369.53%
FY2018	2.7×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/B ratio	Change
Sep 2026	35.5×	—
Jun 2026	0.0×	—
Mar 2026	76.0×	(17.37%)
Dec 2025	92.0×	—
33 more quarters	Free account

Against its own ten years

Low 0.0× High 101×

Ten-year median 3.4×

Current reading's percentile 88

Company	P/B ratio
BCRX BioCryst Pharmaceuticals, Inc. compare	n/m
ALVO Alvotech compare	n/m
RGC Regencell Bioscience Holdings Limited compare	n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare	n/m
PRGO Perrigo Company plc compare	0.9×
PBH Prestige Consumer Healthcare Inc. compare	1.1×
TRLV Trulieve Cannabis Corp. compare	2.9×
AMLX Amylyx Pharmaceuticals, Inc. compare	13.6×
XERS Xeris Biopharma Holdings, Inc.	56.2×
Drug Manufacturers Specialty & Generic industry median	1.7×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Xeris Biopharma Holdings, Inc. (XERS) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on XERS

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on XERS

Stockrow Weekly